£15 million Pharmaceutical Collaboration
The MRC PPU have announced the renewal of their major collaboration with the pharmaceutical industry.
Agreement has been reached with six of the world's major pharmaceutical companies (AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline, Merck Co Inc. (USA), Merck KGaA (Germany) and Pfizer) to renew support of the Division of Signal Transduction Therapy (DSTT). The aim of this research collaboration is to facilitate the development of improved drugs to treat cancer, diabetes, rheumatoid arthritis and other serious diseases that target two classes of regulatory enzyme termed protein kinases and protein phosphatases. The companies will provide funding of more than £15 million over five years - almost double the amount awarded for the previous five years. This is thought to be one of the largest collaborations ever reached between the pharmaceutical industry and a UK research institution.
Agreement has been reached with six of the world's major pharmaceutical companies (AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline, Merck Co Inc. (USA), Merck KGaA (Germany) and Pfizer) to renew support of the Division of Signal Transduction Therapy (DSTT). The aim of this research collaboration is to facilitate the development of improved drugs to treat cancer, diabetes, rheumatoid arthritis and other serious diseases that target two classes of regulatory enzyme termed protein kinases and protein phosphatases. The companies will provide funding of more than £15 million over five years - almost double the amount awarded for the previous five years. This is thought to be one of the largest collaborations ever reached between the pharmaceutical industry and a UK research institution.